Malcom Persen - Nephros Director
| NEPH Stock | USD 2.19 0.05 2.34% |
Director
Mr. Malcom C. Persen is Director of the Company. Mr. Persen is currently the President of Resolute Performance Contracting, a solar construction firm that he founded in 2011. Previously, from 2009 through 2011, he was the Executive Vice President at Ironco Enterprises, a renewable energy contracting organization. From 2004 through 2008, Mr. Persen served as the Chief Financial Officer for Radyne Corporationrationration, a NASDAQtraded manufacturer and distributor of satellite and telecommunications equipment. While at Radyne, he was part of the management team that tripled revenues and sold the firm, resulting in a 100 percent return for shareholders. Earlier, Mr. Persen was employed as Group Financial Officer for Avnet, Inc., a global distributor of electronic components and computer systems. Other experience included assignments with consultancies Arthur D. Little and Mercer Management Consulting. In addition, Mr. Persen lectured in finance at the University of Arizona from 2010 to 2013 and at Boston College from 1988 to 1999. Mr. Persen currently serves on the Board of Valutek, a supplier of cleanroom supplies through direct and distribution channels since 2015.
| Age | 60 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 380 Lackawanna Place, South Orange, NJ, United States, 07079 |
| Phone | 201 343 5202 |
| Web | https://www.nephros.com |
Nephros Management Efficiency
The company has return on total asset (ROA) of (0.0871) % which means that it has lost $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1827) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Nephros' Asset Turnover is increasing as compared to previous years.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Babich | Teleflex Incorporated | 69 | |
| Henry Becton | Becton Dickinson and | 72 | |
| Colleen Jay | The Cooper Companies | 58 | |
| Donald Press | The Cooper Companies | 79 | |
| Timothy Ring | Becton Dickinson and | 63 | |
| Andrew Eckert | Becton Dickinson and | 56 | |
| Ron Taylor | ResMed Inc | 67 | |
| Basil Anderson | Becton Dickinson and | 70 | |
| Thomas Bahen | Alcon AG | N/A | |
| Gretchen Haggerty | Teleflex Incorporated | 65 | |
| Carlos Toledo | Alcon AG | N/A | |
| Karen Drexler | ResMed Inc | 60 | |
| Alain Chevassus | AptarGroup | 72 | |
| Jesse Wu | AptarGroup | 62 | |
| Rich Sulpizio | ResMed Inc | 65 | |
| Peter Pfeiffer | AptarGroup | 66 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| Raymond Blight | Alcon AG | N/A | |
| David Melcher | Becton Dickinson and | 66 | |
| Maria Rivas | The Cooper Companies | 57 | |
| David Burgstahler | AngioDynamics | 47 | |
Management Performance
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0871 |
Nephros Leadership Team
Elected by the shareholders, the Nephros' board of directors comprises two types of representatives: Nephros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nephros. The board's role is to monitor Nephros' management team and ensure that shareholders' interests are well served. Nephros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nephros' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Malcom Persen, Director | ||
| Vashone Thomas, Regulatory, Quality | ||
| Thomas Gwydir, Director | ||
| Joleen Turner, VP Devel | ||
| Paul Mieyal, Director | ||
| Greg Lucas, President Systems | ||
| Robert Banks, CEO President | ||
| Alfred Vargas, Director Operations | ||
| Daron Evans, CEO and President Acting CFO, Director and Member of Audit Committee | ||
| Judy CFA, Chief Officer | ||
| Judy Mazzini, Controller | ||
| MS MBA, Inc Products | ||
| Andrew Astor, CFO, CEO | ||
| Alisa Lask, Director | ||
| Matthew Rosenberg, Director | ||
| Moshe Pinto, Director | ||
| Arthur Amron, Independent Director | ||
| Oliver Spandow, Director | ||
| Brianne McGuire, Marketing Brand |
Nephros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nephros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0871 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.20) % | |||
| Current Valuation | 20.62 M | |||
| Shares Outstanding | 10.54 M | |||
| Shares Owned By Insiders | 12.22 % | |||
| Shares Owned By Institutions | 40.73 % | |||
| Number Of Shares Shorted | 1.61 K | |||
| Price To Earning | (4.51) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Nephros in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Nephros' short interest history, or implied volatility extrapolated from Nephros options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.272 | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.